Unknown

Dataset Information

0

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?


ABSTRACT: BACKGROUND:This study assessed the impact of simultaneous achievement of clinical, functional and structural efficacy, herein referred to as comprehensive disease control (CDC), on short-term and long-term work-related outcomes, health-related quality of life (HRQoL), pain and fatigue. METHODS:Data were pooled from three randomised trials of adalimumab plus methotrexate for treatment of early-stage or late-stage rheumatoid arthritis (RA). CDC was defined as 28-joint Disease Activity Score using C reactive protein <2.6, Health Assessment Questionnaire <0.5 and change from baseline in modified Total Sharp Score ?0.5. Changes in scores at weeks 26 and 52 for work-related outcomes, Short Form 36 (SF-36) physical (PCS) and mental component scores (MCS), a Visual Analogue Scale measuring pain (VAS-Pain) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were compared between patient groups defined by achievement of CDC at week 26 using linear regression with adjustment for baseline scores. RESULTS:Patients with RA who achieved CDC at week 26 (n=200) had significantly greater improvements in VAS-Pain (46.9 vs 26.9; p<0.0001), FACIT-F (13.3 vs 7.5; p<0.0001), SF-36 PCS (19.7 vs 8.9; p<0.0001) and SF-36 MCS (8.1 vs 5.0; p=0.0004) than those who did not (n=1267). Results were consistent at week 52 and among methotrexate-naive patients with early RA, methotrexate-experienced patients with late-stage RA and patients with inadequate response to methotrexate. CONCLUSIONS:Patients with RA who achieved CDC at week 26 had improved short-term and long-term HRQoL, pain, fatigue and work-related outcomes compared with patients who do not. These results demonstrate that the joint achievement of all CDC components provides meaningful benefits to patients. TRIAL REGISTRATION NUMBERS:DE019: NCT00195702, PREMIER: NCT00195702, OPTIMA: NCT00195702.

SUBMITTER: Emery P 

PROVIDER: S-EPMC4680119 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?

Emery Paul P   Kavanaugh Arthur A   Bao Yanjun Y   Ganguli Arijit A   Mulani Parvez P  

Annals of the rheumatic diseases 20140819 12


<h4>Background</h4>This study assessed the impact of simultaneous achievement of clinical, functional and structural efficacy, herein referred to as comprehensive disease control (CDC), on short-term and long-term work-related outcomes, health-related quality of life (HRQoL), pain and fatigue.<h4>Methods</h4>Data were pooled from three randomised trials of adalimumab plus methotrexate for treatment of early-stage or late-stage rheumatoid arthritis (RA). CDC was defined as 28-joint Disease Activi  ...[more]

Similar Datasets

| S-EPMC5623327 | biostudies-literature
| S-EPMC8612915 | biostudies-literature
| S-EPMC7994312 | biostudies-literature
| S-EPMC5253086 | biostudies-other
| S-EPMC7317912 | biostudies-literature
2019-10-21 | GSE136052 | GEO
| S-EPMC6617097 | biostudies-literature
2005-10-11 | E-SMDB-1874 | biostudies-arrayexpress
| S-EPMC7773768 | biostudies-literature
2017-02-13 | GSE56649 | GEO